Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HERV-K immunotherapy
- Development stage
- Unknown
- Lead developer
- GeNeuro
- Modality
- Vaccines & Immunotherapeutics, Gene Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intramuscular, Intravenous, Parenteral
01
Overview
HERV-K immunotherapy refers to a class of immunotherapeutic strategies designed to target Human Endogenous Retrovirus K (HERV-K), a genetic remnant of ancient retroviral infections integrated into the human genome. While typically silent in healthy tissues, HERV-K is aberrantly reactivated and expressed in various solid tumors (such as colorectal, breast, ovarian, prostate, and pancreatic cancers) as well as in metabolic and neurodegenerative diseases. HERV-K immunotherapies aim to break immune tolerance to these self-antigens, utilizing modalities such as adenoviral vectors, mRNA vaccines, and monoclonal antibodies to stimulate robust humoral and cellular immune responses (including CD4+ and CD8+ T-cell activation) against HERV-K-expressing cells.
- Other names
- HERV-K immunotherapiesHERV-K-targeted immunotherapiesHERV-K-targeted immunotherapy
02
Targets
SLC3A2 (Solute carrier family 3 member 2)NeuraminidaseFcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)HERV-K Env (Human endogenous retrovirus K envelope protein)HERV-K (Human endogenous retrovirus K)
Beyond the preview
Go deeper on HERV-K immunotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HERV-K immunotherapy.